Division of Medical Oncology, Duke University Medical Center, Durham North Carolina, USA.
Clin Cancer Res. 2013 Aug 15;19(16):4326-34. doi: 10.1158/1078-0432.CCR-13-0779. Epub 2013 Jun 14.
Selective BRAF inhibitors have now been established as a standard of care option for patients diagnosed with metastatic melanoma whose tumors carry a BRAF mutation. Their successful development represents a milestone in the treatment of this disease, and has the potential to impact therapy for other malignancies as well. The use of these agents, however, has introduced a number of critical questions about the optimal use and selection of patients for BRAF inhibitor therapy. This review discusses the current status of BRAF inhibitor clinical development, the clinicopathologic features of BRAF-mutated melanoma, as well as strategies for overcoming resistance.
选择性 BRAF 抑制剂现已成为携带 BRAF 突变的转移性黑色素瘤患者的标准治疗选择。它们的成功开发代表了该疾病治疗的一个里程碑，并且有可能对其他恶性肿瘤的治疗产生影响。然而，这些药物的使用提出了一些关于 BRAF 抑制剂治疗的最佳使用和患者选择的关键问题。本文综述了 BRAF 抑制剂临床开发的现状、BRAF 突变黑色素瘤的临床病理特征以及克服耐药性的策略。
